Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Feb;6(2):122-4.
doi: 10.1158/2159-8290.CD-15-1493.

Pruning Cancer's Evolutionary Tree with Lesion-Directed Therapy

Crispin T Hiley  1 , Charles Swanton  2
Affiliations
Comment

Pruning Cancer's Evolutionary Tree with Lesion-Directed Therapy

Crispin T Hiley et al. Cancer Discov. 2016 Feb.

Abstract

Next-generation sequencing of spatially and temporally separated biopsies and circulating tumor DNA directs therapy in response to tumor evolution and acquired resistance in colorectal cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Phylogenetic trees of the patients tumour over the course of therapy. The detectable subclone at each time point is indicated (orange), smaller undetectable subclones are also shown (green). Clones are pruned or grow and expand in response to targeted therapy. No therapy the patient receives is effectively able to target the trunk of the tumour, consequently branches are able to evolve and those with resistance to the targeted therapies are able to expand and are detectable on biopsy or in the ctDNA. (S5 = liver segment 5 lesion, S8 = liver segment 8 lesion)
See this image and copyright information in PMC

Comment on

  • Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.
    Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, Mussolin B, Kwak EL, Buscarino M, Lazzari L, Valtorta E, Truini M, Jessop NA, Robinson HE, Hong TS, Mino-Kenudson M, Di Nicolantonio F, Thabet A, Sartore-Bianchi A, Siena S, Iafrate AJ, Bardelli A, Corcoran RB. Russo M, et al. Cancer Discov. 2016 Feb;6(2):147-153. doi: 10.1158/2159-8290.CD-15-1283. Epub 2015 Dec 7. Cancer Discov. 2016. PMID: 26644315 Free PMC article.

References

    1. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976 Oct 1;194(4260):23–8. - PubMed
    1. Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol. 2014 Sep 12;8(6):1095–111. - PMC - PubMed
    1. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011 Mar 23;3(75):75ra26. - PMC - PubMed
    1. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008 Oct 23;359(17):1757–65. - PubMed
    1. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012 Jun 28;486(7404):532–6. - PMC - PubMed

Publication types